BridgeBio Pharma Inc reports results for the quarter ended June 30 - Earnings Summary

• BridgeBio Pharma Inc BBIO.OQ reported a quarterly adjusted loss of 95 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -39 cents. The mean expectation of eighteen analysts for the quarter was for a loss of 84 cents per share. Wall Street expected results to range from $-1.10 to -40 cents per share.

• Revenue rose 4,999.9% to $110.57 million from a year ago; analysts expected $91.41 million.

• BridgeBio Pharma Inc's reported EPS for the quarter was a loss of 95 cents​.

• The company reported a quarterly loss of $181.9 million.

• BridgeBio Pharma Inc shares had risen by 10.6% this quarter and gained 74.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6.2% in the last three months.​

• In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for BridgeBio Pharma Inc is $60.00, about 20.4% above its last closing price of $47.75

This summary was machine generated from LSEG data August 5 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)